{"product_id":"avns-pestle-analysis","title":"(AVNS) Avanos Medical, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Avanos Medical, Inc. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces affect the company and why it matters for strategy, investing, and risk management; the page includes a real preview\/sample so you can assess style and depth before buying—purchase the full ready-to-use report to unlock the complete company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperations across 6 regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. sells across 6 regions: North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America. That reach increases exposure to import rules, tender systems, and public healthcare budgets that can shift by country and delay orders. Political changes can also alter distributor terms and market access, so even one policy move can affect revenue timing and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. headquarters in Alpharetta, Georgia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a U.S.-based medical device firm, Avanos Medical, Inc. sits under FDA oversight and federal healthcare policy, so any change in device review, labeling, or compliance can affect launches and costs. \u003c\/p\u003e\n\u003cp\u003eMedicare and Medicaid reimbursement can shift hospital buying behavior, especially for procedure-linked products, because payment rates shape what providers can afford to stock. \u003c\/p\u003e\n\u003cp\u003eWith headquarters in Alpharetta, Georgia, Avanos also faces U.S. election-cycle swings in healthcare spending priorities, which can change regulatory pressure and public-payer demand. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect sales to hospitals and care facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. sells directly to hospitals, providers, and care facilities, so public procurement rules and hospital network policies can move demand fast. In publicly funded systems, budget reviews and tender cycles can slow device adoption, especially when capital and supply budgets are tight; OECD health spending is still near 10% of GDP, so policy shifts matter. Even small reimbursement or purchasing changes can quickly affect orders and channel mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-opioid pain management focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos Medical, Inc. sells non-opioid pain tools like On-Q, ambIT, Game Ready, and Coolief, and that fits a policy shift toward opioid-sparing care. In the U.S., the CDC said nonopioid therapies should be used when possible, while opioid-involved overdose deaths still totaled 81,083 in 2023. That keeps political support strong for acute and interventional pain products. Avanos benefits when payers and health systems favor lower-opioid pathways.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePolicy favors nonopioid care and lower-opioid use.\u003c\/li\u003e\n\u003cli\u003e81,083 U.S. opioid deaths in 2023 keep pressure high.\u003c\/li\u003e\n\u003cli\u003eAvanos products fit this care shift well.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDistributor channel in global markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos Medical, Inc. uses third-party wholesale distributors, so its international sales depend on local partners, not just its own team. Cross-border politics can slow customs clearance, trigger sanctions checks, and change licensing rules, which can disrupt delivery and cash flow. The WTO said world goods trade volume grew 2.6% in 2024, but country risk still shapes distributor performance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCustoms delays can hit revenue timing.\u003c\/li\u003e\n\u003cli\u003eSanctions raise compliance risk.\u003c\/li\u003e\n\u003cli\u003eLicensing rules vary by country.\u003c\/li\u003e\n\u003cli\u003eStability drives distributor execution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Faces Policy Risk as Opioid-Sparing Demand Stays Strong\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. faces political risk from FDA oversight, Medicare and Medicaid reimbursement shifts, and public tender rules across 6 regions. The policy tailwind is real for nonopioid care: U.S. opioid-involved deaths were 81,083 in 2023, so payer and government support for opioid-sparing tools stays important.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegions\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. opioid deaths\u003c\/td\u003e\n\u003ctd\u003e81,083 (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorld goods trade growth\u003c\/td\u003e\n\u003ctd\u003e2.6% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps how Political, Economic, Social, Technological, Environmental, and Legal forces shape Avanos Medical, Inc.’s risks, opportunities, and strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick, organized snapshot of Avanos Medical’s PESTLE risks for fast decision-making and easy team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise bibliography of primary, industry, and regulatory sources to fast‑track due diligence and verify Avanos Medical assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital budget pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. relies on hospital and provider budgets, so tight spending can hit orders fast. CMS raised Medicare inpatient hospital payments by 2.9% for FY2025, but wage growth, staffing costs, and inflation still leave many buyers short on cash. That can delay capital device buys and slow consumable replenishment, especially when reimbursement does not cover full cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to multiple currencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. sells across several international regions, so it is exposed to multiple currencies. Foreign exchange swings can lift or cut reported sales and margins when overseas revenue is translated back into U.S. dollars. For multinational medtech firms, currency volatility is a real earnings driver, not just a side risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInput cost inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. faces input cost inflation from plastics, electronics, freight, and labor, which can squeeze gross margin when price hikes lag. In fiscal 2025, this matters because even a small delay in passing through higher supply costs can hit earnings fast. Global supply cost inflation remains a direct risk for a medical device maker.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProcedure volumes and elective care cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos Medical, Inc. sells more when hospitals run more procedures, because pain and respiratory devices track elective case flow. When the economy weakens, elective surgeries are often deferred, so utilization falls; when hospital throughput improves, sales volumes usually recover.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore elective cases = higher device use\u003c\/li\u003e\n\u003cli\u003eSlowdowns can delay surgeries\u003c\/li\u003e\n\u003cli\u003eHospital recovery supports volume growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInterest rates and financing conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWith U.S. policy rates still in the 4%+ range, Avanos Medical, Inc. faces a tighter financing backdrop: higher debt costs can cool hospital capex, slow purchasing, and make customers stretch out approval cycles. In medtech, that also trims M\u0026amp;A valuations and can push management to favor cash conservation over aggressive buybacks or deals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher rates lift borrowing costs.\u003c\/li\u003e\n\u003cli\u003eHospitals delay non-urgent buys.\u003c\/li\u003e\n\u003cli\u003eM\u0026amp;A multiples can compress.\u003c\/li\u003e\n\u003cli\u003eCapital allocation turns more selective.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Faces Hospital Budget Squeeze as Rates Stay High\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. is exposed to hospital budget pressure: CMS raised FY2025 inpatient payments 2.9%, but wage and supply inflation still squeeze buyers. Higher rates also slow capex and stretch approval cycles. A weaker economy can delay elective procedures, cutting device use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS FY2025\u003c\/td\u003e\n\u003ctd\u003e+2.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolicy rates\u003c\/td\u003e\n\u003ctd\u003e4%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX risk\u003c\/td\u003e\n\u003ctd\u003eMargin swing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAvanos Medical, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Avanos Medical, Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use; it covers political, economic, social, technological, legal, and environmental factors with actionable insights and no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging patient population\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePeople 65+ now make up about 1 in 6 people worldwide, and that share keeps rising in 2025. Older adults use more chronic care and pain products, and age-linked needs for enteral feeding, respiratory support, and longer recovery periods all rise, which supports Avanos Medical, Inc.'s device demand. In the U.S., 58 million people were 65+ in 2024, a large base for these categories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeonatal and pediatric care needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. serves neonatal and pediatric care needs through NeoMed feeding and airway support, a niche that matters because about 10% of newborns need some form of special care at birth. Families and clinicians value safer enteral feeding and airway management in the first days of life, when small errors can have outsized harm. Demographic pressure also helps: the U.S. still recorded about 3.6 million births in 2024, sustaining demand for specialized early-life products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreference for opioid-sparing pain care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePreference for opioid-sparing pain care is rising as U.S. opioid-involved overdose deaths still reached 81,083 in 2023, pushing hospitals to cut dependence risk. Patients and clinicians now favor non-opioid options, which supports Avanos Medical, Inc.’s interventional pain and cold therapy products. That shift can help growth as care teams seek safer, lower-addiction pain control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eShift toward home and long-term care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnteral feeding and chronic care are moving from acute hospitals to home and long-term care, so Avanos Medical, Inc. needs products that work with less clinician support. One bad setup can affect safety, so clear labels, simple steps, and patient training matter more.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHome care use is rising\u003c\/li\u003e\n\u003cli\u003eSafety must be easy at home\u003c\/li\u003e\n\u003cli\u003eTraining reduces user errors\u003c\/li\u003e\n\u003cli\u003eDesign must fit caregivers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInfection control expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos Medical, Inc. benefits when hospitals prioritize infection control, because closed airway suction and airway management devices help limit contamination and fit strict clinical protocols. In U.S. care settings, infection prevention remains a top buying filter, so devices that support safer workflows can lift adoption and brand trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower contamination risk supports purchase decisions\u003c\/li\u003e\n\u003cli\u003eFits hospital infection control protocols\u003c\/li\u003e\n\u003cli\u003eTrust improves when safety is visible\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging and opioid caution drive Avanos demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSocietal aging, home care use, and tighter infection control support Avanos Medical, Inc. demand. In 2025, about 1 in 6 people worldwide are 65+, while the U.S. had 58 million people 65+ in 2024 and 3.6 million births in 2024, keeping pressure on geriatric, neonatal, and pediatric care.\u003c\/p\u003e\n\u003cp\u003eOpioid caution also helps Avanos Medical, Inc., as U.S. opioid-involved overdose deaths hit 81,083 in 2023, pushing non-opioid pain care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAging\u003c\/td\u003e\n\u003ctd\u003e1 in 6 global 65+ in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. base\u003c\/td\u003e\n\u003ctd\u003e58M 65+; 3.6M births in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCoolief interventional pain platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoolief shows Avanos Medical, Inc.’s strength in minimally invasive pain care, where radiofrequency ablation can reduce pain through precise nerve targeting. Adoption depends on clinical proof, procedural accuracy, and strong physician training, because outcomes vary if placement is off. In a crowded pain market, Coolief’s technology edge is a key differentiator for Avanos.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOn-Q and ambIT pump systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. says its On-Q and ambIT acute pain pumps are used in surgical settings, where reliability, dosing control, and simple setup matter most. In FY2025, Avanos reported net sales of about $0.7 billion, so pump performance still has a direct link to revenue and clinician trust. If delivery is inconsistent, patient recovery and adoption can slip fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnteral feeding device engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. leans on 3 core digestive health brands: Mic-Key, Corpak, and NeoMed. In enteral feeding device engineering, tube design, placement accuracy, and patient comfort drive adoption and safety. Material upgrades and smarter delivery systems can cut clogging, improve usability, and lower complication risk in a market where even small design gains can affect outcomes and cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAirway management product design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBallard, Microcuff, and EndoClear are built for respiratory care tasks where tiny design details matter: suction, airway sealing, and fast clinical use. In airway management, better cuff pressure control and cleaner suction paths can lower complications, and CDC data show ventilator-associated pneumonia can raise mortality and ICU cost, so hospitals favor devices that help reduce risk.\u003c\/p\u003e\n\u003cp\u003eAvanos Medical, Inc. also benefits when its product design supports smoother workflows, since ICU teams manage many patients at once and even small time savings matter. With U.S. hospital spending still under pressure, airway tools that improve seal reliability and ease of use can strengthen purchasing preference.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrecision engineering supports safer suction.\u003c\/li\u003e\n\u003cli\u003eSeal quality helps limit airway leaks.\u003c\/li\u003e\n\u003cli\u003eWorkflow speed matters in ICU care.\u003c\/li\u003e\n\u003cli\u003eLower complications can lift hospital demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical evidence and usability testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos Medical, Inc. depends on clinical evidence and usability testing because hospitals buy devices that show clear outcomes and fit existing care paths. In FY2025, that meant pairing R\u0026amp;D with clinician feedback, since even small workflow frictions can slow adoption and raise training time. Ease of use matters as much as performance, especially when staff must learn fast. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProve outcomes before scale-up.\u003c\/li\u003e\n\u003cli\u003eKeep training simple and short.\u003c\/li\u003e\n\u003cli\u003eMatch hospital protocols closely.\u003c\/li\u003e\n\u003cli\u003eUse clinician feedback in R\u0026amp;D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Wins on Precision, Usability, and Clinical Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. depends on device design, clinician training, and workflow fit. In FY2025, net sales were about $0.7 billion, so product reliability across Coolief, On-Q, and enteral and respiratory lines still links directly to adoption, repeat use, and hospital trust. Better precision, easier setup, and fewer complications matter most.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTechnological factor\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrecision engineering\u003c\/td\u003e\n\u003ctd\u003eDrives safer outcomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUsability\u003c\/td\u003e\n\u003ctd\u003eSpeeds staff adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical evidence\u003c\/td\u003e\n\u003ctd\u003eSupports purchasing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkflow fit\u003c\/td\u003e\n\u003ctd\u003eProtects revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA medical device oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. sells into a tightly regulated U.S. device market, where FDA 510(k) clearance, Quality System Regulation compliance, and post-market reporting are mandatory before launch. In FY2025, any FDA review delay can still shift launch timing by months and slow cash conversion, especially for products tied to hospital budgets and procedure schedules. The company also faces recall and adverse-event reporting risk, so stronger quality control directly protects revenue access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU MDR and international approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. must clear local rules in Europe and other markets before sales can scale, so each launch adds time and cost. The EU Medical Device Regulation, in force since 26 May 2021, has pushed much heavier clinical evidence and technical-file demands, which raises the bar for product approval and post-market surveillance. Multi-country approvals also mean parallel filings, audits, and label updates, so compliance overhead can rise fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct liability and recall exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFeeding tubes, airway devices, and pain pumps can trigger product liability claims if defects or adverse events reach patients. Avanos Medical, Inc. operates in a category where a single recall can bring FDA warnings, litigation, and cleanup costs, so quality control is a legal shield, not just an ops metric. In FY2025, this matters because even one high-severity recall can hit sales, margins, and cash flow fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAnti-kickback and reimbursement compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos Medical, Inc. faces strict anti-kickback and reimbursement rules because device makers can trigger U.S. False Claims Act exposure, where civil penalties in 2025 can reach $13,946 to $27,894 per claim, plus treble damages. Payments, samples, speaker fees, and distributor incentives tied to hospitals or physicians are closely reviewed.\u003c\/p\u003e\n\u003cp\u003eReimbursement codes and marketing claims also create risk if they overstate medical necessity or steer buying decisions. For Avanos Medical, Inc., even small compliance gaps can hit margins fast, because one billing error can cascade across payer audits, chargebacks, and contract disputes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnti-kickback rules raise fraud risk.\u003c\/li\u003e\n\u003cli\u003ePhysician ties face close scrutiny.\u003c\/li\u003e\n\u003cli\u003eMarketing claims can trigger audits.\u003c\/li\u003e\n\u003cli\u003eBilling errors can mean treble damages.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrivacy and contract obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare customers now demand tight privacy, cybersecurity, and procurement terms, and Avanos Medical, Inc. must meet them to win and keep contracts. GDPR fines can reach €20 million or 4% of global turnover, so data handling and vendor controls are not side issues.\u003c\/p\u003e\n\u003cp\u003eContract wording also matters because breach notice, audit, and service-level clauses can slow or block partnerships. If supplier standards slip, contract enforcement risk rises fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrivacy clauses affect deal access\u003c\/li\u003e\n\u003cli\u003eCybersecurity terms drive due diligence\u003c\/li\u003e\n\u003cli\u003eSupplier standards can trigger disputes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Faces Heavy FDA, FCA, and GDPR Compliance Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. faces FDA, EU MDR, product-liability, and anti-kickback rules that can delay launches, raise compliance cost, and trigger recalls or litigation. In FY2025, False Claims Act penalties can reach $13,946-$27,894 per claim, plus treble damages. GDPR fines can hit €20 million or 4% of global turnover.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. device law\u003c\/td\u003e\n\u003ctd\u003eFDA delay\/recall risk\u003c\/td\u003e\n\u003ctd\u003e510(k), QSR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFraud law\u003c\/td\u003e\n\u003ctd\u003eFCA exposure\u003c\/td\u003e\n\u003ctd\u003e$13,946-$27,894\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivacy law\u003c\/td\u003e\n\u003ctd\u003eData penalty risk\u003c\/td\u003e\n\u003ctd\u003e€20m or 4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-use device waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSingle-use medical devices create disposal waste after one use, and hospitals are under pressure to cut landfill volume and sort waste better. The WHO says health care generates about 15% hazardous waste, so product design and packaging choices matter.\u003c\/p\u003e\n\u003cp\u003eFor Avanos Medical, Inc., sustainability now has to sit next to safety and infection control, not replace them. Devices that reduce material use, improve recyclability, or support safer segregation can fit buyer expectations and lower waste costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePackaging and sterilization footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. faces higher packaging and sterilization footprints because sterile devices need multi-layer wraps, trays, and controlled handling. US hospitals generate about 5.9 million tons of waste a year, so packaging cuts now matter more for cost and ESG scrutiny. The push is to use less material, keep sterility, and improve recyclability without raising contamination risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal logistics emissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. ships across regions, so air, ocean, and last-mile transport all add carbon. Global shipping moves about 80% of world trade and is responsible for roughly 3% of global CO2 emissions, so route choice matters. Better network design, fuller loads, and more local fulfillment can cut freight emissions and lower fuel cost exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate-related supply chain disruption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClimate shocks can hit Avanos Medical, Inc. at every step: floods, storms, and heat can stop plant output, slow warehousing, and delay transport. In the U.S., NOAA logged 28 billion-dollar weather disasters in 2023, showing how often logistics can be stressed. For healthcare suppliers, dual sourcing, safety stock, and backup routes are no longer optional.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eWeather can halt production and shipping.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eDelivery delays raise service risk.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eResilience plans now protect margins.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical waste disposal rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedical waste disposal rules are strict because healthcare waste includes sharps, used devices, and contaminated materials; the WHO says about 15% of healthcare waste is hazardous, so Avanos Medical, Inc. must design products and packaging for safe handling and compliant disposal.\u003c\/p\u003e\n\u003cp\u003eThese rules raise costs for customers and suppliers, since mislabeling, poor segregation, or unsafe transport can trigger fines, recalls, and service disruption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHazardous waste is about 15% of healthcare waste\u003c\/li\u003e\n\u003cli\u003eSharps and contaminated items need controlled disposal\u003c\/li\u003e\n\u003cli\u003eCompliance affects Avanos Medical, Inc. and its supply chain\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Can Cut Waste Without Compromising Sterility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos Medical, Inc. must cut waste, packaging, and transport emissions while keeping sterility intact. Healthcare waste is about 15% hazardous, US hospitals generate about 5.9 million tons yearly, and weather shocks keep raising supply risk, so resilient sourcing and leaner materials matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHazardous waste\u003c\/td\u003e\n\u003ctd\u003e15% of healthcare waste\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospital waste\u003c\/td\u003e\n\u003ctd\u003e5.9 million tons\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClimate risk\u003c\/td\u003e\n\u003ctd\u003eResilience needs dual sourcing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234117165321,"sku":"avns-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/avns-pestle-analysis.webp?v=1785712163","url":"https:\/\/dcfanalyst.com\/products\/avns-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}